ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks.

For detailed information, see the URL below.

https://www.businesswire.com/news/home/20210728005557/en/ENYO-Pharma-Announces-Positive-Vonafexor-EYP001-Results-for-the-LIVIFY-Phase-2a-Study-in-F2-F3-NASH-Patients-over-12-weeks

Vonafexor is a synthetic non-steroidal, non-Bile Acid, highly selective FXR agonist.  This is used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was presented at AASLD 2019.

http://www.enyopharma.com/wp-content/uploads/2019/11/2019-AASLD-Radreau-et-al-Preclinical-NASH.pdf

In the future, we believe that further clinical trial results for Vonafexor will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.